Testing Drug Responses Using Tumor Models Grown From Glioblastoma Patients
Studies whether lab-grown tumor models from patients predict how glioblastoma responds to treatment.
Key facts
- Who runs it
- Chungnam National University Hospital
- Where
- Daejeon, South KoreaSee the site
- Trial code
- Registry title
- Drug Response Testing and Repurposing Using Glioblastoma Organoid
- Status
- Recruiting
- People taking part
- 150 people, planned
- Started
- 18 Aug 2021
- Expected to end
- Dec 2030
- Type of study
- Observational
- Treatments tested
- Organoid-based drug sensitivity test
- Record updated
- 20 January 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with primary or recurrent glioblastoma who had standard treatment and have enough tumor tissue to grow an organoid in the lab.
- Sex
- All sexes can join.
- Disease stage
- Primary or recurrent glioblastoma.
- Earlier treatment
- Standard treatment with surgery and chemoradiation therapy that includes temozolomide.
Main reasons for not taking part
- Did not have concurrent chemoradiation therapy (CCRT) after surgery
- No MRI scan could be obtained after CCRT
- Refuses to take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- primary or recurrent glioblastoma
- patients treated with standard treatment including surgery and temozolomide based chemoradiation therapy
- sufficient tumor sample is available for organoid culture
Who cannot take part
- patients who are not underwent concurrent chemoradiation therapy (CCRT) following surgery
- failed to obtain MRI scan after CCRT
- patients refusal
Where in South Korea
- Chungnam National University HospitalDaejeon, South KoreaContact: Kyung Hwan Kim, MD, PhDTaking people
About the trial
What the trial wants to find out
The aim of this observational study, based on a prospectively collected cohort, is to evaluate the prognostic value of patient-derived organoids in predicting responses to conventional and repurposing drugs, including temozolomide, in patients with primary or recurrent glioblastoma. The primary question is whether the patient's response to temozolomide is recapitulated in their corresponding patient-derived glioblastoma organoid (GBO). Patient drug responses are evaluated using survival data, while GBO drug responses are assessed through a drug-response testing platform utilizing cell viability assays. Additionally, this platform is used to explore the potential application of various chemotherapeutic agents.
The group in the trial
- glioblastoma
prospectively enrolled
Treatment: Organoid-based drug sensitivity test
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Patient-derived Organoids As Predictive Models for Drug Response Testing and Repurporsing in Glioblastoma Therapy
- Plain-language title
- Testing Drug Responses Using Tumor Models Grown From Glioblastoma PatientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 20 January 2025